Why Wall Street is Betting Heavily Against Sarepta Therapeutics
Despite the FDA recently providing a regulatory pathway for Sarepta's Duchenne muscular dystrophy drug, the stock is still one of the most heavily shorted in health care. Here's why.
What You Need to Know About PTC Therapeutics' Promising DMD Drug
PTC Therapeutics (PTCT) won support from a key EU advisory committee last month, potentially clearing the way for a drug launch next year.
Tuesday’s Top Biotech Stories: Vanda Pharmaceuticals, Prosensa, and Clovis Oncology
Vanda Pharmaceuticals, Prosensa, and Clovis Oncology could all loom large in health care headlines this morning. Here’s why.
Surprising MS Drug Approval: Time to Buy?
The EU has issued a preliminary approval for Translarn, the Duchenne muscular dystrophy drug developed by PTC Therapeutics.